News & Updates
Filter by Specialty:

Atezolizumab-bevacizumab provides optimal balance between survival, QoL benefits in HCC
05 Jun 2025
byAudrey Abella
A network meta-analysis (NMA) reports that the combination regimen comprising atezolizumab and bevacizumab appears to be better than other first-line systemic therapeutic alternatives for advanced hepatocellular carcinoma (HCC) in terms of providing a balance between overall survival (OS) benefit and quality of life (QoL) preservation.
Atezolizumab-bevacizumab provides optimal balance between survival, QoL benefits in HCC
05 Jun 2025
Phase IIb study supports lorundrostat for treatment-resistant hypertension
04 Jun 2025
byAudrey Abella
The phase IIb Advance-HTN trial shows the blood pressure (BP)-lowering effect of lorundrostat in patients with uncontrolled and treatment-resistant hypertension (HTN).
Phase IIb study supports lorundrostat for treatment-resistant hypertension
04 Jun 2025
WAYFINDER updates boost tezepelumab role in OCS-dependent severe asthma
03 Jun 2025
byAudrey Abella
Updated results from the open-label, phase IIIb WAYFINDER study continue to support the oral corticosteroid (OCS)-sparing efficacy of tezepelumab in the treatment of patients with OCS-dependent severe asthma.